my65roses4me
New member
<span style=" font-size: x-small;">Guaifenesin is what is in
Robitussin.<br>
Very interesting article;<br>
http://sharedjourney.com/articles/guaf.html<br>
<h1 id="nointelliTXT"><span style=" font-size: small;">Improvement
of Cervical Factor with Guaifenesin</h1>
<div style=" float: left;"><script type="text/javascript"><!--
google_ad_client = "pub-5253809430940410";
google_ad_width = 300;
google_ad_height = 250;
google_ad_format = "300x250_as";
google_ad_type = "text_image";
google_ad_channel ="3976085354";
google_color_border = "FFFFFF";
google_color_bg = "FFFFFF";
google_color_link = "154F80";
google_color_url = "000000";
google_color_text = "000000";
//--></script><script type="text/javascript"
src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script><iframe
src=
"http://pagead2.googlesyndication.com/pagead/ads?client=ca-pub-5253809430940410&dt=1158549358062&lmt=1158549358&format=300x250_as&output=html&channel=3976085354&url=http%3A%2F%2Fsharedjourney.com%2Farticles%2Fguaf.html&color_bg=FFFFFF&color_text=000000&color_link=154F80&color_url=000000&color_border=FFFFFF&ad_type=text_image&cc=2810&u_h=768&u_w=1024&u_ah=738&u_aw=1024&u_cd=32&u_tz=-420&u_his=58&u_java=true"
marginwidth="0" allowtransparency="" width="300" scrolling="no"
height="250" marginheight="0" frameborder="0" name=
"google_ads_frame"></iframe></div>
<p class="author">by Jerome H. Check,M.D., H.G Adleson, B.S.,<br>
Chung-Hsis Wu, M.D.
Guaifenesin is an exportant capable of increasing respiratory
tract fluid. It is a common ingredient of many antitussive
preparations. A study was designed to see whether this agent could
also improve cervical mucus, as manifested by improved sperm
survival and fertility.
<b>Materials and Methods</b><br>
Forty couples with a minumum of 10 months of infertility were
selected where there was no sperm motility on postcoital testing.
Hostile cervical mucus rather than defective spermatogenesis was
assumed on the basis of accepting in the study only those couples
where the baseline spermogram after 48 hours abstinence had at
least a count of 25 x 10 6/cc, a 2-cc volume, 70% motility, grade 3
of 4 quality, and less than 20% abnormal forms.
The postcoital test was performed on the 2nd day before the
temperature rise. Two baseline postcoital tests with no sperm
motility 2 hours after intercourse were required before the couple
was entered in the study. After wiping off the cervix with cotton,
the mucus was aspirated with a tuberculin syringe. If the mucus
quality (spinn-barkeit, ferning, lack of cellularity) was good but
with no sperm motility, the couple was not included in the study.
Similarly, if cervical mucus was absent, the couple was not
accepted for the study.
Ovulation was established on the basis of a serum progesterone
level x2 over 10/ng/ml taken 1 week before menses and a biphasic
basal body temperature chart with a minimum of a 13-day luteal
phase. IF drug therapy was required to establish ovulation, the
couple could be selected as long as the drug required was not
clomiphene citrate and/or human menopausal gonadotropins.
Each woman was treated with 200mg guaifenesin orally three times
daily from day 5 to her temperature rise in either the commonly
available antitussive elixir form or in capsule form.
Response to guaifenesin as reflected by postcoital evaluation
was scored as "no improvement" (no motile sperm),
"marked improvement" (at least 3 to 5 sperm per
high-powered field with good linear progressive motion), or
"slight improvement" (some motile sperm but a number or
quality of motility inferior to standards set for the "marked
improvement" category). Mucus quality was juddered before and
after guaifenesin as to spinnbarkeit and cellularity. If the
patient showed some improvement in the postcoital test, then the
therapy was continued for a minimum of 6 months unless conception
occurred first. If there still was no sperm survival after two
treatment cycles, the therapy was considered a failure and was
stopped. Though the patient would then be treated with other
methods, as far as this study was concerned she would only be
listed in the "no improvement" category. No patient in
the study was allowed to have treatment with any other therapy that
could positively or negatively influence the cervical mucus.
The tubal factor was investigated by either hysterosalpingogram
or laparoscopy. Seventy percent of the patients had a
laparoscopy.
<table cellspacing="1" bgcolor="#e3575f" border="1" cellpadding="3"
width="100%">
<tr>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%">
<p align="center">Total
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">Marked Improvement
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">Slight Improvement
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">No Improvement
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">Number of patients in
Subgroup</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">40
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">23 (57.5%)
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">7 (17.5%)
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">10 (25%)
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">I
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">10
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">8
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">1
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">1
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">II
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">30
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">15
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">6
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">9
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">Number pregnant</td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">I
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">8
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">7
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">1
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">II
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">8
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">8
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">% pregnant</td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">I
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">80
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">87.5
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">100
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">II
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">26.6
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">53
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">Total</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">40
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">65.2
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">14.3
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
</tr>
</TBODY></table>
<b>Results</b>
The response to guafenesin is seen in Table 1. Twenty-three of
40 patients showed marked improvement in postcoital following
treatment, while 7 showed slight improvement was associated with
improvement in the mucus quality (improved spinnbarkeit and
decreased cellularity).
Fifteen pregnancies in 23 couples (65.2%) occurred in the group
showing marked improvement in the postcoital tests after guafenesin
therapy. One patient with only a mild improvement in sperm survival
achieved a pregnancy. In ten patients with hostile mucus as the
only detectable cause of the infertility, eight became pregnant in
an average 2.4 months. In the remaining eight patients achieving
pregnancies, where other fertility problems coexisted, there was an
average of 5.6 months of treatments with guaifenesin. One patient,
despite a marked improvement in sperm survival and no other
apparent cause for infertility, did not achieve a pregnancy after 6
months of guaifenesin therapy. Only one of seven patients showing a
slight improvement in sperm survival achieved pregnancy. The
failure of eight patients to achieve pregnancies despite marked
improvement in sperm survival can BA accounted for by other
associated fertility problems.
<b>Discussion</b>
The results indicate that guafenesin may improve cervical mucus
and improve fertility. A double-blind study was not deemed
necessary, since it was easy to follow the objective parameter of
sperm survival and correlate this with subsequent fertility. There
is no evidence that psychological factors can adversely affect
cervical mucus in the presence of ovulation. The exact mechanism of
action of guafenesin is not known, though it would seem to be
reasonably similar to its mechanism of improving respiratory tract
secretions. Other methods of treating the cervical factor have been
reviewed by Blasco. An additional technique employing high-dose
estrogen in combination with human menopausal gonadotropins has
been described more recently. The quoted pregnancy statistic
following conventional therapy of the cervical factor has been
under 30%. With guafenesin therapy 40% of the entire cervical
factor group conceived. In the subgroup of patients whose fertility
problem seemed likely to be related to the cervical factor only,
80% conceived. These statistics will probably improve when
guaifenesin therapy is combined with other treatment modalities for
the cervical factor.
Fertility and Sterility<br>
May 1982
<br>
<br>
<span style=" font-size: x-small;">{Let me know what you
think}
Robitussin.<br>
Very interesting article;<br>
http://sharedjourney.com/articles/guaf.html<br>
<h1 id="nointelliTXT"><span style=" font-size: small;">Improvement
of Cervical Factor with Guaifenesin</h1>
<div style=" float: left;"><script type="text/javascript"><!--
google_ad_client = "pub-5253809430940410";
google_ad_width = 300;
google_ad_height = 250;
google_ad_format = "300x250_as";
google_ad_type = "text_image";
google_ad_channel ="3976085354";
google_color_border = "FFFFFF";
google_color_bg = "FFFFFF";
google_color_link = "154F80";
google_color_url = "000000";
google_color_text = "000000";
//--></script><script type="text/javascript"
src="http://pagead2.googlesyndication.com/pagead/show_ads.js"></script><iframe
src=
"http://pagead2.googlesyndication.com/pagead/ads?client=ca-pub-5253809430940410&dt=1158549358062&lmt=1158549358&format=300x250_as&output=html&channel=3976085354&url=http%3A%2F%2Fsharedjourney.com%2Farticles%2Fguaf.html&color_bg=FFFFFF&color_text=000000&color_link=154F80&color_url=000000&color_border=FFFFFF&ad_type=text_image&cc=2810&u_h=768&u_w=1024&u_ah=738&u_aw=1024&u_cd=32&u_tz=-420&u_his=58&u_java=true"
marginwidth="0" allowtransparency="" width="300" scrolling="no"
height="250" marginheight="0" frameborder="0" name=
"google_ads_frame"></iframe></div>
<p class="author">by Jerome H. Check,M.D., H.G Adleson, B.S.,<br>
Chung-Hsis Wu, M.D.
Guaifenesin is an exportant capable of increasing respiratory
tract fluid. It is a common ingredient of many antitussive
preparations. A study was designed to see whether this agent could
also improve cervical mucus, as manifested by improved sperm
survival and fertility.
<b>Materials and Methods</b><br>
Forty couples with a minumum of 10 months of infertility were
selected where there was no sperm motility on postcoital testing.
Hostile cervical mucus rather than defective spermatogenesis was
assumed on the basis of accepting in the study only those couples
where the baseline spermogram after 48 hours abstinence had at
least a count of 25 x 10 6/cc, a 2-cc volume, 70% motility, grade 3
of 4 quality, and less than 20% abnormal forms.
The postcoital test was performed on the 2nd day before the
temperature rise. Two baseline postcoital tests with no sperm
motility 2 hours after intercourse were required before the couple
was entered in the study. After wiping off the cervix with cotton,
the mucus was aspirated with a tuberculin syringe. If the mucus
quality (spinn-barkeit, ferning, lack of cellularity) was good but
with no sperm motility, the couple was not included in the study.
Similarly, if cervical mucus was absent, the couple was not
accepted for the study.
Ovulation was established on the basis of a serum progesterone
level x2 over 10/ng/ml taken 1 week before menses and a biphasic
basal body temperature chart with a minimum of a 13-day luteal
phase. IF drug therapy was required to establish ovulation, the
couple could be selected as long as the drug required was not
clomiphene citrate and/or human menopausal gonadotropins.
Each woman was treated with 200mg guaifenesin orally three times
daily from day 5 to her temperature rise in either the commonly
available antitussive elixir form or in capsule form.
Response to guaifenesin as reflected by postcoital evaluation
was scored as "no improvement" (no motile sperm),
"marked improvement" (at least 3 to 5 sperm per
high-powered field with good linear progressive motion), or
"slight improvement" (some motile sperm but a number or
quality of motility inferior to standards set for the "marked
improvement" category). Mucus quality was juddered before and
after guaifenesin as to spinnbarkeit and cellularity. If the
patient showed some improvement in the postcoital test, then the
therapy was continued for a minimum of 6 months unless conception
occurred first. If there still was no sperm survival after two
treatment cycles, the therapy was considered a failure and was
stopped. Though the patient would then be treated with other
methods, as far as this study was concerned she would only be
listed in the "no improvement" category. No patient in
the study was allowed to have treatment with any other therapy that
could positively or negatively influence the cervical mucus.
The tubal factor was investigated by either hysterosalpingogram
or laparoscopy. Seventy percent of the patients had a
laparoscopy.
<table cellspacing="1" bgcolor="#e3575f" border="1" cellpadding="3"
width="100%">
<tr>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%">
<p align="center">Total
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">Marked Improvement
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">Slight Improvement
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">No Improvement
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">Number of patients in
Subgroup</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">40
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">23 (57.5%)
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">7 (17.5%)
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">10 (25%)
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">I
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">10
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">8
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">1
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">1
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">II
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">30
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">15
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">6
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">9
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">Number pregnant</td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">I
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">8
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">7
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">1
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">II
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">8
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">8
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">% pregnant</td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
<td bgcolor="#ffffff" width="20%"> </td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">I
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">80
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">87.5
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">100
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">
<p align="center">II
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">26.6
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">53
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
</tr>
<tr>
<td bgcolor="#ffffff" width="20%">Total</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">40
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">65.2
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">14.3
</td>
<td bgcolor="#ffffff" width="20%">
<p align="center">0
</td>
</tr>
</TBODY></table>
<b>Results</b>
The response to guafenesin is seen in Table 1. Twenty-three of
40 patients showed marked improvement in postcoital following
treatment, while 7 showed slight improvement was associated with
improvement in the mucus quality (improved spinnbarkeit and
decreased cellularity).
Fifteen pregnancies in 23 couples (65.2%) occurred in the group
showing marked improvement in the postcoital tests after guafenesin
therapy. One patient with only a mild improvement in sperm survival
achieved a pregnancy. In ten patients with hostile mucus as the
only detectable cause of the infertility, eight became pregnant in
an average 2.4 months. In the remaining eight patients achieving
pregnancies, where other fertility problems coexisted, there was an
average of 5.6 months of treatments with guaifenesin. One patient,
despite a marked improvement in sperm survival and no other
apparent cause for infertility, did not achieve a pregnancy after 6
months of guaifenesin therapy. Only one of seven patients showing a
slight improvement in sperm survival achieved pregnancy. The
failure of eight patients to achieve pregnancies despite marked
improvement in sperm survival can BA accounted for by other
associated fertility problems.
<b>Discussion</b>
The results indicate that guafenesin may improve cervical mucus
and improve fertility. A double-blind study was not deemed
necessary, since it was easy to follow the objective parameter of
sperm survival and correlate this with subsequent fertility. There
is no evidence that psychological factors can adversely affect
cervical mucus in the presence of ovulation. The exact mechanism of
action of guafenesin is not known, though it would seem to be
reasonably similar to its mechanism of improving respiratory tract
secretions. Other methods of treating the cervical factor have been
reviewed by Blasco. An additional technique employing high-dose
estrogen in combination with human menopausal gonadotropins has
been described more recently. The quoted pregnancy statistic
following conventional therapy of the cervical factor has been
under 30%. With guafenesin therapy 40% of the entire cervical
factor group conceived. In the subgroup of patients whose fertility
problem seemed likely to be related to the cervical factor only,
80% conceived. These statistics will probably improve when
guaifenesin therapy is combined with other treatment modalities for
the cervical factor.
Fertility and Sterility<br>
May 1982
<br>
<br>
<span style=" font-size: x-small;">{Let me know what you
think}